CSF2 and breast cancer: While there was no overall benefit seen in the vaccinated group, there seems to be a benefit in patients with low HER2 expression and TNBC.80,81 Another HER2-derived peptide vaccine, E75 also known as nelipepimut-S (NP-S) or even better known as NeuVax, has been evaluated in a Phase I-III clinical trials (NCT00841399/NCT00584789/NCT01479244).77 HLA-A2+ or A3+ and low HER2 expression breast cancer patients were treated with E75 in combination with GM-CSF monthly for 6 months and then every 6 months until 36 months.